-
公开(公告)号：US11110154B2
公开(公告)日：2021-09-07
申请号：US14706747
申请日：2015-05-07
IPC分类号： A61K38/00 , A61K39/00 , A61K48/00 , A61P25/00 , A61P25/14 , A61P25/28 , C07K19/00 , C12N15/62 , C12N15/86 , A61K38/54 , A61K38/46 , A61K38/18 , A61K38/17 , C12N15/864 , C12N15/63
摘要： Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
-
公开(公告)号：US11104691B2
公开(公告)日：2021-08-31
申请号：US15507203
申请日：2015-08-28
发明人： Celia Dominguez , John Wityak , Jonathan Bard , Alex Kiselyov , Christopher John Brown , Michael Edward Prime , Peter David Johnson , Daniel Clark-Frew
IPC分类号： A61K51/00 , A61M36/14 , C07D519/00 , C07D471/04 , A61K51/04
摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
-
公开(公告)号：US10765764B2
公开(公告)日：2020-09-08
申请号：US16172425
申请日：2018-10-26
发明人： Celia Dominguez , John Wityak , Jonathan Bard , Christopher John Brown , Michael Edward Prime , Peter David Johnson , Thomas Martin Krulle , Daniel Clark-Frew , Duane Higgins , Matthew Robert Mills , Richard Waldron Marston , Samuel Coe , Samantha Brown , Sarah Hayes
IPC分类号： A61K51/04 , C07D513/04 , C07D487/04 , C07D513/14 , C07B59/00
摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
-
公开(公告)号：US10457675B2
公开(公告)日：2019-10-29
申请号：US16049482
申请日：2018-07-30
发明人： Celia Dominguez , Ignacio Muñoz-Sanjuán , Roland W. Bürli , Christopher A. Luckhurst , Daniel R. Allen , Gilles Raphy , Perla Breccia , Alan F. Haughan , Grant Wishart , Samantha J. Hughes , Rebecca E. Jarvis , Huw D. Vater , Stephen D. Penrose , Michael Wall , Andrew J. Stott , Elizabeth A. Saville-Stones
IPC分类号： C07D417/04 , C07D231/54 , C07D401/04 , C07D403/04 , C07D239/70 , C07D239/74 , C07D239/88 , C07D277/60 , C07C259/08 , C07D231/56 , C07D275/04
摘要： Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.
-
5.发明授权公开(公告)号：US10442782B2
公开(公告)日：2019-10-15
申请号：US15813001
申请日：2017-11-14
发明人： Leticia M. Toledo-Sherman , Celia Dominguez , Michael Prime , William Leonard Mitchell , Peter Johnson , Naomi Went
IPC分类号： C07D311/20 , C07D307/79 , C07D263/58 , C07D235/26 , C07D319/18 , C07D317/46 , C07D215/18 , C07C62/38 , C07D307/94 , C07D309/10 , C07D311/58 , C07D317/60 , C07D233/64 , C07D403/10 , C07D405/08 , C07D405/10 , C07D405/12 , C07C317/44 , C07D413/08 , C07D413/10 , C07C323/62 , C07C229/22 , C07C229/46 , C07C229/48 , C07D257/04 , C07D203/08 , C07C235/82 , C07D207/08 , C07D271/07 , C07D207/337 , C07D295/155 , C07D305/06 , C07D305/08 , C07D307/54 , C07D307/80 , C07C69/757 , C07D203/10 , C07D413/12 , C07H15/20
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
公开(公告)号：US10137211B2
公开(公告)日：2018-11-27
申请号：US15249223
申请日：2016-08-26
发明人： Celia Dominguez , John Wityak , Jonathan Bard , Christopher John Brown , Michael Edward Prime , Peter David Johnson , Thomas Martin Krulle , Daniel Clark-Frew , Duane Higgins , Matthew Robert Mills , Richard Waldron Marston , Samuel Coe , Samantha Brown , Sarah Hayes
IPC分类号： A61K51/04 , C07D513/04 , C07D487/04 , C07D513/14 , C07B59/00
摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use
-
7.发明授权Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof 有权犬奈宁-3-单加氧酶抑制剂，药物组合物及其使用方法公开(公告)号：US09428464B2
公开(公告)日：2016-08-30
申请号：US14241699
申请日：2012-08-28
申请人： Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson , Celia Dominguez , Leticia M. Toledo-Sherman , Ignacio Muñoz-Sanjuan
发明人： Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson , Celia Dominguez , Leticia M. Toledo-Sherman , Ignacio Muñoz-Sanjuan
IPC分类号： C07D239/52 , A61K31/506 , C07D239/28 , C07D403/12 , C07D403/06 , C07D405/12 , C07D413/12 , C07D491/048 , C07D239/42 , C07D401/04 , C07D401/12 , C07D417/12 , C07D471/04 , C07D487/04
CPC分类号： C07D239/28 , A61K31/506 , C07D239/42 , C07D239/52 , C07D401/04 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/048 , Y02A50/401 , Y02A50/411 , Y02A50/465
摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。
-
公开(公告)号：US09057066B2
公开(公告)日：2015-06-16
申请号：US13708839
申请日：2012-12-07
发明人： Gene Hung , Janet M. Leeds , C. Frank Bennett , Susan M. Freier
IPC分类号： C07H21/02 , A01N43/04 , C12N15/113
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/111 , C12N2310/31 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/323 , C12N2310/3231 , C12N2310/33 , C12N2310/3341 , C12N2310/335 , C12N2310/341 , C12N2310/346 , C12N2320/30 , C12N2310/3525
摘要： Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
摘要翻译： 本文公开了用于调节细胞，组织或动物中亨廷丁氏蛋白的表达的化合物，组合物和方法。 还提供了使用靶向亨廷顿汀的反义化合物减慢或预防亨廷顿病进展的方法。 另外提供的方法是延缓或预防在亨廷顿病易感的个体中亨廷顿病发病的方法。 还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。
-
9.发明授权Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof 有权转谷氨酰胺酶TG2抑制剂，药物组合物及其使用方法公开(公告)号：US08889716B2
公开(公告)日：2014-11-18
申请号：US13466018
申请日：2012-05-07
申请人： Michael Prime , Stephen Martin Courtney , Richard Marston , Celia Dominguez , Douglas MacDonald , John Wityak
发明人： Michael Prime , Stephen Martin Courtney , Richard Marston , Celia Dominguez , Douglas MacDonald , John Wityak
IPC分类号： A61K31/445 , C07D211/96 , C07D409/12 , C07D205/04 , C07D405/12 , C07D405/14 , C07D207/48 , C07D401/14 , C07D401/12
CPC分类号： C07D205/04 , C07D207/48 , C07D211/96 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12
摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.
摘要翻译： 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。
-
公开(公告)号：US20240342317A1
公开(公告)日：2024-10-17
申请号：US18402399
申请日：2024-01-02
发明人： Longbin Liu , Matthew Lee , Celia Dominguez , Peter David Johnson , Catherine Jane Greenaway , Kanika Khurana , Matthew Robert Mills , Filippo Rota
IPC分类号： A61K51/04 , C07B59/00 , C07D231/12 , C07D471/04 , C07D487/04 , C07D487/14 , C07D519/00
CPC分类号： A61K51/0459 , A61K51/0455 , A61K51/0463 , C07B59/002 , C07D231/12 , C07D471/04 , C07D487/04 , C07D487/14 , C07D519/00 , C07B2200/05
摘要： Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
-
-
-
-
-
-
-
-
-
搜索结果
69 条记录 (耗时 0.039 秒)
